Introduction and Objective: The standard treatment for central precocious puberty is the use of gonadotropin-releasing hormone agonists; nevertheless, there is still no agreement on those who have not acquired adequate control of puberty with a standard dose of GnRh agonist. Therefore, this study was conducted aiming to determine the response ratio to the Triptorelin Acetate Treatment Program in adequate control of the central precocious puberty of girls referred to endocrinology clinic of Kashan University of Medical Sciences from 2011 to 2017. Materials and Methods: This study as cohort study was performed on 48 girls suffering from central precocious puberty. The treatment with treptorelin acetate was performed once every 28 days, and a clinical examination and measurement of estradiol, LH and FSH levels were performed once every 3 months. The cases without adequate control of puberty based on clinical, laboratory and radiological criteria were treated with a 25-day regimen and in case of the lack of adequate control of puberty, the interval of medicine injection was reduced to 21 days. To analyze the data, the statistical SPSS V.16 software was used. Findings: Totally, 13 (27%) children responded to the once in 28-day regimen and 35 (73%) children were regarded in the once in 25-day treatment due to the lack of adequate control, of which 20 (57%) children were treated and 15 (43%) children were treated with the once in 21-day regimen due to the lack of adequate control, that finally adequate control was created in all patients. Conclusion: In girls suffering from central precocious puberty, that adequate control of puberty is not created by 28-day standard regimen, this aim can be achieved by reducing the injection intervals.
